European Physician Adoption of Advanced Mobile Activities is Increasing

Manhattan ResearchAs mobile devices become more advanced, European physicians are turning to them for a number of uses in their professional practice, according to a recent study by Manhattan Research. About half of online European physicians check email on their mobile devices while nearly four in ten search on a mobile web browser. When it comes to mobile activities for medical content, physicians are currently more likely to conduct straightforward advanced tasks such as reading medical news or checking treatment guidelines, but as physicians' mobile proficiency continues to increase and as browsing capabilities improve, physicians will begin to perform more complex, interactive activities on these devices, such as social networking and patient monitoring.

"As in the U.S., mobile devices are streamlining the medical profession in Europe by allowing doctors to communicate and access clinical resources throughout the day," said Joe Farris, President of Manhattan Research. "While the largest current opportunity for connecting with European physicians is through brief, text-based content, there's future market potential for richer, more engaging mobile interactions."

Complimentary White Paper
Manhattan Research's European eHealth Landscape is a complimentary white paper discussing some of the latest trends in how physicians and patients across Europe use the Internet and technology for health purposes. To access the report, please visit http://www.manhattanresearch.com/research/white-papers/european-ehealth-landscape.aspx.

Manhattan Research eHealth Trends Podcast Series
Manhattan Research produces monthly podcasts on a variety of consumer and physician eHealth topics. In the latest episode, "EU vs. US physicians," Healthcare Analyst Miranda Manganaro discusses differences between European and US physicians when it comes to technology adoption and behavior. Free subscriptions are available immediately via iTunes at http://tinyurl.com/mRiTunes and you can listen to the entire series at http://www.manhattanresearch.com/podcast.

About Taking the Pulse® Europe
Taking the Pulse® Europe is Manhattan Research's market research and advisory service focused on how physicians across Western Europe use the Internet and technology for clinical purposes and for engaging with pharmaceutical companies. Taking the Pulse® Europe v9.0 was fielded online in Q4 2009 among 1,125 practicing physicians in Germany, Spain, France, Italy, and the United Kingdom.

Taking the Pulse® Europe provides in-depth market research on many other physician technology and digital marketing topics, including email communication, smartphone ownership/mobile activities, online journals, virtual conferences, social networking, online video, health and medical website visitation, search engines, patient education, pharma website visitation, videoconferencing with reps, and electronic detailing. In addition to a comprehensive view of the European physician market, clients can also gain insight into the online resource and communication trends for specific country and specialist segments. For more information, please visit http://www.manhattanresearch.com/ttpeu.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the U.S., Europe, and Asia.

For information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...